Who owns KINNATE BIOPHARMA INC?
- CUSIP Number: 49705r105
Tip: Access positions for across all investors
Analyze quarterly positions in Kinnate Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Kinnate Biopharma stock
Who bought or sold KINNATE BIOPHARMA INC this quarter?
There are no current stakeholders of Kinnate Biopharma.
This is normal when the security:
- Has been acquired or taken private
- Has merged with another entity
- Has changed its name and has a new CUSIP (and/or symbol)
- Has been delisted and the ticker has changed
Please use Search to find the security you were looking for.
Who sold out of Kinnate Biopharma?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Foresite Capital Management IV | Mar 2024 | 9.7M | $26M |
OrbiMed Advisors | Mar 2024 | 8.0M | $21M |
Foresite Capital Management V | Mar 2024 | 3.5M | $9.4M |
Lynx1 Capital Management | Mar 2024 | 2.0M | $5.3M |
Viking Global Investors | Mar 2024 | 1.8M | $4.8M |
Susquehanna International | Mar 2024 | 1.3M | $3.3M |
Vanguard Group | Mar 2024 | 1.1M | $2.9M |
Tang Capital Management | Mar 2024 | 978k | $2.6M |
Acadian Asset Management | Mar 2024 | 965k | $2.6M |
Renaissance Technologies | Mar 2024 | 888k | $2.4M |
BlackRock | Mar 2024 | 431k | $1.1M |
Group One Trading | Mar 2024 | 354k | $942k |
Millennium Management | Mar 2024 | 267k | $711k |
Geode Capital Management | Mar 2024 | 244k | $650k |
Citadel Advisors | Mar 2024 | 218k | $579k |
Marshall Wace | Mar 2024 | 156k | $415k |
Deutsche Bank Aktiengesellschaft | Mar 2024 | 115k | $306k |
XTX Topco | Mar 2024 | 104k | $278k |
Dimensional Fund Advisors | Mar 2024 | 92k | $245k |
CSS | Mar 2024 | 69k | $184k |
Goldman Sachs Group | Mar 2024 | 63k | $168k |
Susquehanna Portfolio Strategies | Mar 2024 | 49k | $129k |
Jane Street | Mar 2024 | 42k | $113k |
Leucadia National Corporation | Mar 2024 | 41k | $108k |
Cowen And Company | Mar 2024 | 25k | $67k |
Jpmorgan Chase & Co | Mar 2024 | 25k | $66k |
Squarepoint Ops | Mar 2024 | 23k | $62k |
Simplex Trading | Mar 2024 | 22k | $57k |
Occudo Quantitative Strategies | Mar 2024 | 21k | $56k |
BBR Partners | Mar 2024 | 20k | $53k |
Shay Capital | Mar 2024 | 19k | $52k |
Florida State Board of Administration | Mar 2024 | 14k | $89k |
Barclays | Mar 2024 | 14k | $38k |
Point72 Asia | Mar 2024 | 14k | $38k |
Virtu Financial | Mar 2024 | 11k | $30k |
Morgan Stanley | Mar 2024 | 7.4k | $20k |
Qube Research & Technologies | Mar 2024 | 6.3k | $17k |
Cubist Systematic Strategies | Mar 2024 | 4.1k | $11k |
Rhumbline Advisers | Mar 2024 | 2.9k | $7.8k |
Bank of America Corporation | Mar 2024 | 1.8k | $4.5k |
Tower Research Capital | Mar 2024 | 1.1k | $2.9k |